View all news

Humanigen Reports Additional Analysis of Lenzilumab in Severe and Critical COVID-19 Patients

Jun 16, 2020
  • Lenzilumab median time to recovery of five days compares favorably to remdesivir’s 10 days in a similar patient group

  • Lenzilumab Phase 3 potential registration study ongoing in severe and critical COVID-19 patients

  • Humanigen to host a webinar today at 4:30 p.m. ET to discuss results of the initial cohort of patients treated with lenzilumab


Burlingame, CA, June 16, 2020 Humanigen, Inc., (HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating cytokine storm with lenzilumab, the company’s proprietary Humaneered® anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody, announced additional analysis on the first clinical use of lenzilumab in 12 COVID-19 patients. The manuscript, titled ‘First Clinical Use of Lenzilumab to Neutralize GM-CSF in Patients with Severe and Critical COVID-19 Pneumonia,’ was published online at medRxiv.org, (https://www.medrxiv.org/content/10.1101/2020.06.08.20125369v2).


A secondary analysis was conducted by Humanigen comparing patients with similar baseline characteristics treated with lenzilumab to patients treated with remdesivir. Results of this analysis are shown in the table below. Patients treated with lenzilumab showed rapid clinical improvement with a median time to improvement of five days and a median time to recovery of five days. In comparison, patients treated with remdesivir demonstrated a median time to improvement of 10 to 11 days and median time to recovery of 10 to 11 days1.  Remdesivir was granted emergency use authorization based on time to recovery of 11 days in the Adaptive COVID-19 Treatment Trial (ACTT-1)2.

Multimedia Files:

Categories: Press Releases
View all news